The German government will not get exclusive access to Curevac’s Covid-19 vaccine as part of its 23% stake purchase, the company insists.
With a $3.2bn valuation ahead of its Nasdaq float – and a market cap that is now 50% higher – Legend Biotech enters the IPO record books.
The UK big pharma group unveils funding and a clinical programme that could overshadow the efforts of its biotech rival.
On the back of coronavirus mania, Moderna, a $30bn company heavily funded by the US government, taps investors for $1.3bn.
Moderna becomes the latest coronavirus vaccine player to act on the need for a major manufacturing push.
Next week’s virtual meeting could resuscitate Ox40 agonists, but an important omission will disappoint.
From research collaborations to changes to drug development, pharma will have to find new ways of working to discover Covid-19 treatments.
Industry-sponsored clinical studies against the new coronavirus have proliferated, as have their designs and efficacy measures.
What is biopharma doing to develop vaccines against Covid-19, and what are the properties of each approach? Vantage takes a look.